Vanguard Group
DMRA

Vanguard Group’s Damora Therapeutics DMRA Stock Holding History

Vanguard Group’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$420K Buy
+18,247
New +$317K ﹤0.01% 3976
2024
Q3 		– Sell
-8,848
Closed -$105K – 4356
2024
Q2 		$105K Hold
8,848
– – ﹤0.01% 4229
2024
Q1 		$173K Hold
8,848
– – ﹤0.01% 4195
2023
Q4 		$159K Buy
8,848
+156
+2% +$2.4K ﹤0.01% 4251
2023
Q3 		$156K Buy
8,692
+2,854
+49% +$112K ﹤0.01% 4291
2023
Q2 		$368K Buy
5,838
+3,192
+121% +$174K ﹤0.01% 4197
2023
Q1 		$132K Buy
2,646
+1,063
+67% +$56.1K ﹤0.01% 4372
2022
Q4 		$45.5K Buy
1,583
+214
+16% +$8.88K ﹤0.01% 4454
2022
Q3 		$65K Hold
1,369
– – ﹤0.01% 4522
2022
Q2 		$59K Buy
1,369
+341
+33% +$15.6K ﹤0.01% 4576
2022
Q1 		$57K Hold
1,028
– – ﹤0.01% 4614
2021
Q4 		$78K Sell
1,028
-82
-7% -$6.44K ﹤0.01% 4618
2021
Q3 		$99K Buy
1,110
+128
+13% +$13.7K ﹤0.01% 4529
2021
Q2 		$124K Buy
+982
New +$134K ﹤0.01% 4398

Other funds holding DMRA

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JG
Jain Global New York $25.4B AUM 45.67% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group's DMRA Position: Q4 2025 in Review

Vanguard Group opened a new position in Damora Therapeutics (DMRA) in Q4 2025: 18,247 shares worth $420K. The stake represents ﹤0.01% of the portfolio and ranks #3976 among its holdings. This is a return to the name: Vanguard Group previously reported a position in DMRA as recently as Q2 2024.

Vanguard Group first reported a position in DMRA in Q2 2021 and has held it in 14 quarters since. 18 funds tracked by Wall St. Rank hold DMRA as of Q4 2025.

  • Vanguard Group held 18,247 shares of Damora Therapeutics worth $420K as of Q4 2025.
  • Damora Therapeutics was a new Vanguard Group position in Q4 2025.
  • Damora Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3976 holding.
  • Vanguard Group first reported a position in Damora Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • 18 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.